• Publications
  • Influence
Burden of Rotavirus Disease in European Union Countries
TLDR
To estimate the burden of rotavirus disease in the EU, a model based on the approach developed by the Centers for Disease Control and Prevention was adapted to the European situation and applied it to recent population and mortality data from European countries. Expand
Regression models for disease prevalence with diagnostic tests on pools of serum samples.
TLDR
Joint pool and sample size calculations using information from individual contributors to the pool are performed and it is shown that a good design can severely reduce cost and yet increase precision. Expand
Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials
TLDR
Analysis of this large database shows the HPV-16/18 AS04-adjuvanted cervical cancer vaccine to have a favorable safety profile in women of all ages. Expand
Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases.
TLDR
No consistent significant associations were found between TCVs and neuro developmental outcomes and studies with uniform neurodevelopmental assessments of children with a range of cumulative thimerosal exposures are needed. Expand
Vaccinations and risk of central nervous system demyelinating diseases in adults.
TLDR
Vaccination against hepatitis B, influenza, tetanus, measles, or rubella is not associated with an increased risk of multiple sclerosis or optic neuritis. Expand
The Use of Combination Vaccines Has Improved Timeliness of Vaccination in Children
TLDR
Up-to-date vaccination increased for Hib, polio and HBV in Germany with the change from mono- to 4-, 5- and 6-valent vaccines, and the use of combination vaccines has also significantly improved timeliness of immunizations. Expand
Review of 8 years of experience with Infanrix hexa™ (DTPa–HBV–IPV/Hib hexavalent vaccine)
TLDR
Data show DTPa–HBV–IPV/Hib to be highly immunogenic and well tolerated across a range of different primary and booster vaccination schedules, as well as when administered concomitantly with other licensed vaccines (e.g., pneumococcal conjugate vaccine). Expand
Rotavirus serotype G9 is associated with more-severe disease in Latin America.
TLDR
Demonstration of efficacy against G9 will be an important asset of any rotavirus vaccine to be introduced into a Latin American country or any country where G9 has been shown to be prevalent. Expand
Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers
TLDR
Preliminary results in the subset of subjects who were enrolled with known SARS-CoV-2 seropositivity at baseline show that CVnCoV is also safe and well tolerated in this population, and is able to boost the pre-existing immune response even at low dose levels. Expand
Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines.
TLDR
This integrated analysis of over 68,000 participants who received AS04 adjuvanted vaccines or controls demonstrated a low rate of autoimmune disorders, without evidence of an increase in relative risk associated with AS04Adjuvant vaccines. Expand
...
1
2
3
4
5
...